A reproducible accelerated in vitro release testing method for PLGA microspheres.
The objective of the present study was to develop a discriminatory and reproducible accelerated in vitro release method for long-acting PLGA microspheres with inner structure/porosity differences. Risperidone was chosen as a model drug. Qualitatively and quantitatively equivalent PLGA microspheres with different inner structure/porosity were obtained using different manufacturing processes. Physicochemical properties as well as degradation profiles of the prepared microspheres were investigated. Furthermore, in vitro release testing of the prepared risperidone microspheres was performed using the most common in vitro release methods (i.e., sample-and-separate and flow through) for this type of product. The obtained compositionally equivalent risperidone microspheres had similar drug loading but different inner structure/porosity. When microsphere particle size appeared similar, porous risperidone microspheres showed faster microsphere degradation and drug release compared with less porous microspheres. Both in vitro release methods investigated were able to differentiate risperidone microsphere formulations with differences in porosity under real-time (37 °C) and accelerated (45 °C) testing conditions. Notably, only the accelerated USP apparatus 4 method showed good reproducibility for highly porous risperidone microspheres. These results indicated that the accelerated USP apparatus 4 method is an appropriate fast quality control tool for long-acting PLGA microspheres (even with porous structures).
['Shen|Jie|J|', 'Lee|Kyulim|K|', 'Choi|Stephanie|S|', 'Qu|Wen|W|', 'Wang|Yan|Y|', 'Burgess|Diane J|DJ|']
D002626:Chemistry, Pharmaceutical D019344:Lactic Acid D008863:Microspheres D010316:Particle Size D011100:Polyglycolic Acid D000077182:Polylactic Acid-Polyglycolic Acid Copolymer D015203:Reproducibility of Results
Accelerated in vitro release PLGA microspheres Risperidone Compositionally equivalent Porous USP apparatus 4